IC
DRUG

Ikarian Capital’s Bright Minds Biosciences DRUG Stock Holding History

Ikarian Capital’s Portfolio DRUG Stock Details DRUG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.24M Sell
88,951
-77,696
-47% -$6.1M 0.67% 43
2026
Q1 		$12.2M Buy
166,647
+7,226
+5% +$582K 0.99% 24
2025
Q4 		$12.4M Buy
159,421
+143,990
+933% +$9.62M 0.97% 30
2025
Q3 		$936K Sell
15,431
-50,000
-76% -$1.94M 0.09% 120
2025
Q2 		$1.71M Hold
65,431
– – 0.33% 72
2025
Q1 		$2.36M Sell
65,431
-86,780
-57% -$3.18M 0.29% 66
2024
Q4 		$5.48M Buy
+152,211
New +$5.36M 0.75% 38
2022
Q3 		– Sell
-21,192
Closed -$86K – 125
2022
Q2 		$86K Hold
21,192
– – 0.02% 132
2022
Q1 		$161K Buy
21,192
+1,192
+6% +$13.4K 0.02% 171
2021
Q4 		$317K Buy
+20,000
New +$445K 0.05% 147

Other funds holding DRUG

JT
Jupiter Topco New York $245B AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Ikarian Capital's DRUG Position: Q2 2026 in Review

Ikarian Capital reduced its Bright Minds Biosciences (DRUG) stake by 47% in Q2 2026, selling an estimated $6.1M and leaving 88,951 shares worth $6.24M. The position accounts for 0.67% of the portfolio, ranked #43.

Ikarian Capital first reported a position in DRUG in Q4 2021 and has held it in 10 quarters since. The position peaked at $12.4M in Q4 2025. 99 funds tracked by Wall St. Rank hold DRUG as of Q2 2026.

  • Ikarian Capital held 88,951 shares of Bright Minds Biosciences worth $6.24M as of Q2 2026.
  • Ikarian Capital sold 77,696 Bright Minds Biosciences shares in Q2 2026, an estimated $6.1M.
  • Bright Minds Biosciences made up 0.67% of Ikarian Capital's portfolio in Q2 2026, its #43 holding.
  • Ikarian Capital first reported a position in Bright Minds Biosciences in Q4 2021 and has held it in 10 quarters since.
  • Ikarian Capital's Bright Minds Biosciences position peaked at $12.4M in Q4 2025.
  • 99 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q2 2026.

Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.